Buprenorphine is used in opioid dependence treatment. Its pharmacological profile that makes it suitable includes:

• A Full mu-opioid agonist activity with rapid hepatic first-pass metabolism limiting abuse potential
• B Pure kappa-opioid agonist producing analgesia without euphoria or respiratory depression
• C Selective delta-opioid agonist that reduces opioid craving without receptor cross-tolerance to mu-opioids
• D Partial mu-opioid agonist with high receptor affinity and slow dissociation, producing ceiling effect for respiratory depression and blocking full agonist effects (opioid blockade) ✓

Explanation

Buprenorphine is a partial mu-opioid receptor agonist with very high receptor affinity (slow dissociation, long duration). Its partial agonism creates a ceiling effect on respiratory depression even at high doses. Its tight receptor binding displaces full agonists, reducing their effect. These properties make it effective for substitution therapy: it prevents withdrawal, reduces cravings, and has a lower overdose risk compared with methadone (a full agonist).

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.